Metrnl in mitigating radiation enteritis via label-retaining cells protection by modulating the c-KIT-WNT pathway.

Authors

Sailong Zhang, Simin Chen, Bingjie Guo, Qisheng Ling, Shuling Wang, Zhuwei Miao, Zhi Wang, Yuchen Wei, Sili Zheng, Zhiyong Li, An-Qiang Feng, Feng-Hua Qian, Chao-Yu Miao

Published in

Acta pharmaceutica Sinica. B. Volume 16. Issue 9. Pages 6129-6144. Epub Jun 18, 2026.

Abstract

Currently, there exists no definitive standardized therapy for radiation enteritis. This study unveils Metrnl as a pivotal regulator of intestinal radioprotection through multi-dimensional single-cell profiling and mechanistic dissection. We first demonstrate that radiation dynamically reprograms Metrnl expression in a time-dependent manner, revealing its role as a radiation-responsive mediator. Crucially, Metrnl confers potent protection against radiation-induced intestinal injury through double mechanisms; Metrnl safeguards label-retaining cells (LRCs) rather than conventional Lgr5⁺ intestinal stem cells, and activates a novel c-KIT-WNT signaling axis via ERK/GSK3β-mediated pathway crosstalk, both revitalizing intestinal epithelial regeneration. Therapeutically, recombinant Metrnl emerges as a potential biotherapeutic, effectively attenuating radiation enteritis. These findings establish Metrnl as a key mediator bridging radiation biology and regenerative medicine, offering a transformative potential for radiation injury management.

PMID:
42765054
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.